volume 95, issue 5, P1003-1012 2012
DOI: 10.3945/ajcn.111.030114
View full text
|
|
Share

Abstract: Compared with SFA intake, n-6 PUFAs reduce liver fat and modestly improve metabolic status, without weight loss. A high n-6 PUFA intake does not cause any signs of inflammation or oxidative stress. Downregulation of PCSK9 could be a novel mechanism behind the cholesterol-lowering effects of PUFAs. This trial was registered at clinicaltrials.gov as NCT01038102.

Search citation statements

Order By: Relevance

Citation Types

19
248
4
6

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals